| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 39 | 2026 | 2324 | 4.310 |
Why?
|
| Acute Coronary Syndrome | 8 | 2022 | 295 | 1.630 |
Why?
|
| Immunosuppressive Agents | 11 | 2024 | 834 | 1.600 |
Why?
|
| American Heart Association | 12 | 2025 | 356 | 1.570 |
Why?
|
| Cardiovascular Agents | 7 | 2018 | 165 | 1.450 |
Why?
|
| Heart Transplantation | 16 | 2026 | 674 | 1.380 |
Why?
|
| Atrial Fibrillation | 17 | 2026 | 555 | 1.320 |
Why?
|
| Substance Abuse Detection | 4 | 2025 | 106 | 1.320 |
Why?
|
| Medical Marijuana | 4 | 2024 | 122 | 1.320 |
Why?
|
| Health Resources | 4 | 2016 | 130 | 1.320 |
Why?
|
| Stroke Volume | 9 | 2026 | 650 | 1.120 |
Why?
|
| Substance-Related Disorders | 5 | 2025 | 1090 | 1.110 |
Why?
|
| Graft Rejection | 7 | 2025 | 512 | 1.070 |
Why?
|
| Marijuana Smoking | 2 | 2021 | 249 | 1.020 |
Why?
|
| Anti-Arrhythmia Agents | 13 | 2014 | 141 | 1.010 |
Why?
|
| Polypharmacy | 5 | 2023 | 94 | 0.990 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2019 | 251 | 0.980 |
Why?
|
| Humans | 185 | 2026 | 144667 | 0.970 |
Why?
|
| Drug Interactions | 14 | 2021 | 401 | 0.950 |
Why?
|
| Cocaine | 3 | 2024 | 161 | 0.930 |
Why?
|
| Health Expenditures | 3 | 2025 | 194 | 0.910 |
Why?
|
| Music | 2 | 2024 | 48 | 0.880 |
Why?
|
| Defibrillators, Implantable | 11 | 2001 | 381 | 0.880 |
Why?
|
| Electric Countershock | 9 | 2001 | 127 | 0.870 |
Why?
|
| Drug Overdose | 2 | 2022 | 371 | 0.870 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2022 | 259 | 0.860 |
Why?
|
| Propanolamines | 3 | 2019 | 40 | 0.850 |
Why?
|
| Opioid-Related Disorders | 4 | 2026 | 601 | 0.820 |
Why?
|
| Cardiovascular Diseases | 10 | 2025 | 2172 | 0.790 |
Why?
|
| Cost of Illness | 3 | 2014 | 322 | 0.770 |
Why?
|
| Aminobutyrates | 1 | 2023 | 31 | 0.750 |
Why?
|
| Consensus | 3 | 2024 | 475 | 0.750 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2024 | 127 | 0.740 |
Why?
|
| Theophylline | 1 | 2022 | 41 | 0.730 |
Why?
|
| Drugs, Generic | 2 | 2020 | 27 | 0.720 |
Why?
|
| Arrhythmias, Cardiac | 9 | 2001 | 355 | 0.700 |
Why?
|
| Remote Consultation | 1 | 2022 | 66 | 0.690 |
Why?
|
| Hospitalization | 14 | 2026 | 2446 | 0.690 |
Why?
|
| Nucleic Acids | 1 | 2022 | 72 | 0.670 |
Why?
|
| Organ Transplantation | 2 | 2021 | 247 | 0.650 |
Why?
|
| Male | 98 | 2026 | 72431 | 0.650 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 438 | 0.640 |
Why?
|
| Health Care Costs | 2 | 2014 | 425 | 0.640 |
Why?
|
| Aged | 59 | 2026 | 25955 | 0.640 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 17 | 0.630 |
Why?
|
| Drug Hypersensitivity | 5 | 2008 | 89 | 0.620 |
Why?
|
| Middle Aged | 68 | 2026 | 35971 | 0.600 |
Why?
|
| Cardiovascular System | 1 | 2020 | 136 | 0.570 |
Why?
|
| Anti-Infective Agents | 5 | 2010 | 242 | 0.570 |
Why?
|
| Inpatients | 2 | 2016 | 547 | 0.560 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 194 | 0.560 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 210 | 0.540 |
Why?
|
| United States | 28 | 2026 | 16018 | 0.540 |
Why?
|
| Prescription Drugs | 2 | 2016 | 109 | 0.540 |
Why?
|
| Practice Guidelines as Topic | 5 | 2025 | 1569 | 0.530 |
Why?
|
| Female | 90 | 2026 | 78304 | 0.530 |
Why?
|
| Adult | 50 | 2026 | 40489 | 0.510 |
Why?
|
| Heart Rate | 16 | 2021 | 853 | 0.510 |
Why?
|
| Tachycardia, Ventricular | 10 | 2001 | 180 | 0.510 |
Why?
|
| Sick Leave | 2 | 2014 | 16 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2024 | 1360 | 0.510 |
Why?
|
| Purines | 2 | 2022 | 187 | 0.500 |
Why?
|
| Lung Transplantation | 1 | 2020 | 329 | 0.500 |
Why?
|
| Pregnancy Complications, Cardiovascular | 4 | 2001 | 83 | 0.500 |
Why?
|
| Chronic Disease | 8 | 2020 | 1810 | 0.480 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 38 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 2573 | 0.460 |
Why?
|
| Drug Costs | 3 | 2025 | 117 | 0.460 |
Why?
|
| Anticoagulants | 8 | 2021 | 729 | 0.460 |
Why?
|
| Ranolazine | 1 | 2015 | 23 | 0.460 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 79 | 0.460 |
Why?
|
| Treatment Outcome | 18 | 2025 | 11735 | 0.450 |
Why?
|
| Survival | 1 | 2015 | 38 | 0.450 |
Why?
|
| Angina, Stable | 1 | 2015 | 18 | 0.450 |
Why?
|
| Pharmacists | 5 | 2025 | 240 | 0.450 |
Why?
|
| Retrospective Studies | 23 | 2025 | 17149 | 0.450 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 115 | 0.450 |
Why?
|
| Prescription Drug Misuse | 1 | 2015 | 51 | 0.440 |
Why?
|
| Public Health | 1 | 2020 | 569 | 0.440 |
Why?
|
| Hospital Costs | 1 | 2016 | 125 | 0.440 |
Why?
|
| Cardiac Pacing, Artificial | 9 | 2001 | 84 | 0.440 |
Why?
|
| Calcium Channel Blockers | 2 | 2015 | 165 | 0.430 |
Why?
|
| Employer Health Costs | 1 | 2014 | 4 | 0.430 |
Why?
|
| Physical Therapy Specialty | 2 | 2006 | 55 | 0.430 |
Why?
|
| Drug Monitoring | 5 | 2016 | 396 | 0.420 |
Why?
|
| Cytomegalovirus | 2 | 2025 | 168 | 0.420 |
Why?
|
| Colorado | 10 | 2025 | 4558 | 0.420 |
Why?
|
| Vasodilator Agents | 5 | 2016 | 329 | 0.410 |
Why?
|
| Cardiology | 4 | 2024 | 359 | 0.410 |
Why?
|
| Patient Discharge | 6 | 2021 | 985 | 0.410 |
Why?
|
| Drug Utilization Review | 2 | 2006 | 61 | 0.410 |
Why?
|
| Mortality | 2 | 2015 | 377 | 0.410 |
Why?
|
| Pyrazoles | 2 | 2022 | 512 | 0.410 |
Why?
|
| Electrocardiography | 18 | 2013 | 664 | 0.400 |
Why?
|
| Patient Admission | 1 | 2016 | 220 | 0.400 |
Why?
|
| Methadone | 2 | 2026 | 122 | 0.400 |
Why?
|
| Tacrolimus | 4 | 2016 | 191 | 0.400 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 228 | 0.400 |
Why?
|
| Pain | 3 | 2022 | 785 | 0.400 |
Why?
|
| Aged, 80 and over | 18 | 2026 | 8284 | 0.400 |
Why?
|
| Muscular Diseases | 2 | 2019 | 108 | 0.400 |
Why?
|
| Cytomegalovirus Infections | 2 | 2025 | 205 | 0.390 |
Why?
|
| Daptomycin | 1 | 2013 | 18 | 0.380 |
Why?
|
| Catheter Ablation | 6 | 2000 | 354 | 0.380 |
Why?
|
| Opiate Substitution Treatment | 2 | 2026 | 186 | 0.380 |
Why?
|
| Hospital Mortality | 2 | 2016 | 1033 | 0.380 |
Why?
|
| Creatine Kinase | 1 | 2013 | 72 | 0.370 |
Why?
|
| Drug Prescriptions | 3 | 2010 | 283 | 0.370 |
Why?
|
| Pharmaceutical Services | 1 | 2013 | 76 | 0.360 |
Why?
|
| Australia | 5 | 2026 | 287 | 0.360 |
Why?
|
| Sulfonamides | 5 | 2013 | 579 | 0.360 |
Why?
|
| Baroreflex | 5 | 2021 | 57 | 0.360 |
Why?
|
| Models, Organizational | 1 | 2013 | 143 | 0.360 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 140 | 0.360 |
Why?
|
| Hiccup | 1 | 2011 | 2 | 0.360 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2015 | 81 | 0.350 |
Why?
|
| Dietary Supplements | 4 | 2016 | 575 | 0.350 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2018 | 496 | 0.350 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 18 | 0.350 |
Why?
|
| Risk Factors | 15 | 2026 | 10796 | 0.350 |
Why?
|
| Ventricular Fibrillation | 4 | 2001 | 64 | 0.350 |
Why?
|
| Buprenorphine | 2 | 2026 | 190 | 0.350 |
Why?
|
| Amines | 1 | 2011 | 39 | 0.350 |
Why?
|
| Cities | 1 | 2012 | 143 | 0.340 |
Why?
|
| Medicaid | 1 | 2015 | 464 | 0.340 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 5 | 2000 | 28 | 0.340 |
Why?
|
| Atrioventricular Node | 4 | 1997 | 15 | 0.330 |
Why?
|
| Medication Errors | 3 | 2013 | 82 | 0.330 |
Why?
|
| Cannabinoids | 2 | 2025 | 182 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 1406 | 0.330 |
Why?
|
| Analgesics, Opioid | 4 | 2026 | 1142 | 0.320 |
Why?
|
| Patient Education as Topic | 3 | 2013 | 771 | 0.320 |
Why?
|
| Drug Substitution | 3 | 2020 | 63 | 0.320 |
Why?
|
| Adenosine | 3 | 2018 | 255 | 0.320 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 1209 | 0.310 |
Why?
|
| Heart Conduction System | 9 | 2001 | 96 | 0.310 |
Why?
|
| Aircraft | 3 | 2001 | 23 | 0.310 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 326 | 0.310 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 7 | 0.310 |
Why?
|
| Transplant Recipients | 3 | 2017 | 180 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2024 | 2019 | 0.310 |
Why?
|
| Electrocardiography, Ambulatory | 6 | 1999 | 63 | 0.300 |
Why?
|
| Desensitization, Immunologic | 2 | 2008 | 89 | 0.300 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 227 | 0.300 |
Why?
|
| Clinical Protocols | 3 | 2017 | 282 | 0.290 |
Why?
|
| Seizures | 2 | 2012 | 477 | 0.290 |
Why?
|
| Electrodes, Implanted | 4 | 1997 | 115 | 0.290 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 74 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 392 | 0.280 |
Why?
|
| Restless Legs Syndrome | 1 | 2008 | 20 | 0.270 |
Why?
|
| Premature Birth | 1 | 2012 | 376 | 0.270 |
Why?
|
| Cost Sharing | 1 | 2008 | 20 | 0.270 |
Why?
|
| Citalopram | 1 | 2008 | 32 | 0.270 |
Why?
|
| RNA, Viral | 2 | 2022 | 689 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2025 | 2950 | 0.260 |
Why?
|
| Helicobacter Infections | 1 | 2007 | 30 | 0.260 |
Why?
|
| Ticlopidine | 1 | 2008 | 51 | 0.260 |
Why?
|
| Helicobacter pylori | 1 | 2007 | 45 | 0.260 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 1098 | 0.260 |
Why?
|
| Pacemaker, Artificial | 3 | 2001 | 126 | 0.260 |
Why?
|
| Exanthema | 1 | 2008 | 84 | 0.260 |
Why?
|
| Zygomycosis | 1 | 2007 | 6 | 0.260 |
Why?
|
| Tachycardia, Supraventricular | 6 | 2001 | 45 | 0.250 |
Why?
|
| Carbazoles | 2 | 2011 | 54 | 0.250 |
Why?
|
| Managed Care Programs | 1 | 2008 | 140 | 0.250 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2018 | 22 | 0.250 |
Why?
|
| Imidazolidines | 3 | 2001 | 8 | 0.250 |
Why?
|
| Cyclosporine | 3 | 2010 | 255 | 0.250 |
Why?
|
| Epistaxis | 1 | 2006 | 17 | 0.240 |
Why?
|
| Analgesics | 1 | 2008 | 232 | 0.240 |
Why?
|
| New South Wales | 2 | 2024 | 22 | 0.240 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2006 | 81 | 0.240 |
Why?
|
| Health Behavior | 1 | 2012 | 786 | 0.240 |
Why?
|
| Holidays | 2 | 2024 | 8 | 0.240 |
Why?
|
| Time Factors | 13 | 2026 | 7140 | 0.230 |
Why?
|
| Warfarin | 4 | 2021 | 173 | 0.230 |
Why?
|
| Comorbidity | 6 | 2016 | 1652 | 0.230 |
Why?
|
| Risk Assessment | 8 | 2026 | 3729 | 0.230 |
Why?
|
| Telemedicine | 1 | 2015 | 957 | 0.230 |
Why?
|
| Salvage Therapy | 1 | 2007 | 164 | 0.230 |
Why?
|
| Sympathetic Nervous System | 5 | 2001 | 180 | 0.230 |
Why?
|
| Fructose | 1 | 2006 | 131 | 0.230 |
Why?
|
| Prognosis | 8 | 2025 | 4312 | 0.230 |
Why?
|
| Reagent Strips | 1 | 2025 | 8 | 0.220 |
Why?
|
| Triazoles | 1 | 2007 | 184 | 0.220 |
Why?
|
| Imidazoles | 3 | 2001 | 246 | 0.220 |
Why?
|
| Metronidazole | 1 | 2005 | 20 | 0.220 |
Why?
|
| Diabetic Neuropathies | 1 | 2006 | 99 | 0.220 |
Why?
|
| Medication Adherence | 5 | 2018 | 540 | 0.220 |
Why?
|
| Tobacco, Smokeless | 1 | 2024 | 13 | 0.220 |
Why?
|
| Models, Economic | 2 | 2016 | 61 | 0.220 |
Why?
|
| Heroin Dependence | 1 | 2025 | 33 | 0.220 |
Why?
|
| Ventricular Function, Left | 4 | 2023 | 536 | 0.220 |
Why?
|
| Smoking | 1 | 2012 | 1467 | 0.220 |
Why?
|
| Young Adult | 9 | 2025 | 14122 | 0.210 |
Why?
|
| Coronary Disease | 2 | 1998 | 381 | 0.210 |
Why?
|
| Needle-Exchange Programs | 1 | 2024 | 15 | 0.210 |
Why?
|
| Nitrous Oxide | 1 | 2024 | 35 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 657 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2025 | 133 | 0.210 |
Why?
|
| Mood Disorders | 2 | 2016 | 140 | 0.210 |
Why?
|
| Benzodiazepines | 1 | 2025 | 168 | 0.200 |
Why?
|
| Thrombosis | 2 | 2021 | 396 | 0.200 |
Why?
|
| Piperazines | 3 | 2001 | 378 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 125 | 0.200 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2014 | 57 | 0.200 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2026 | 187 | 0.200 |
Why?
|
| Fentanyl | 1 | 2025 | 127 | 0.200 |
Why?
|
| Metoprolol | 3 | 2001 | 26 | 0.200 |
Why?
|
| Particulate Matter | 1 | 2026 | 337 | 0.200 |
Why?
|
| Vagus Nerve | 2 | 1996 | 92 | 0.190 |
Why?
|
| Research Design | 1 | 2009 | 1129 | 0.190 |
Why?
|
| Cardiac Catheterization | 4 | 2008 | 557 | 0.190 |
Why?
|
| Nurse Clinicians | 1 | 2024 | 43 | 0.190 |
Why?
|
| Endrin | 1 | 2022 | 13 | 0.190 |
Why?
|
| Valsartan | 1 | 2023 | 32 | 0.190 |
Why?
|
| Length of Stay | 3 | 2016 | 1339 | 0.190 |
Why?
|
| Adolescent | 11 | 2024 | 22409 | 0.190 |
Why?
|
| Antiviral Agents | 2 | 2025 | 765 | 0.190 |
Why?
|
| Pressoreceptors | 2 | 2021 | 19 | 0.190 |
Why?
|
| Biphenyl Compounds | 1 | 2023 | 66 | 0.190 |
Why?
|
| Aminophylline | 1 | 2022 | 12 | 0.190 |
Why?
|
| Terminal Care | 2 | 2025 | 283 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 139 | 0.180 |
Why?
|
| Follow-Up Studies | 10 | 2025 | 5414 | 0.180 |
Why?
|
| Sodium | 1 | 2023 | 198 | 0.180 |
Why?
|
| Nitroprusside | 3 | 2016 | 71 | 0.180 |
Why?
|
| Reverse Transcription | 1 | 2022 | 20 | 0.180 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 1044 | 0.180 |
Why?
|
| Fluorobenzenes | 2 | 2013 | 17 | 0.180 |
Why?
|
| Nicotine | 1 | 2024 | 334 | 0.180 |
Why?
|
| Pharmacogenomic Testing | 2 | 2020 | 62 | 0.180 |
Why?
|
| Heart-Assist Devices | 2 | 2021 | 568 | 0.180 |
Why?
|
| Education, Pharmacy | 3 | 2016 | 119 | 0.180 |
Why?
|
| Troponin I | 2 | 2000 | 73 | 0.180 |
Why?
|
| Automation | 1 | 2022 | 104 | 0.180 |
Why?
|
| Patient Transfer | 1 | 2024 | 208 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2026 | 574 | 0.170 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.170 |
Why?
|
| Virus Inactivation | 1 | 2021 | 13 | 0.170 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2021 | 11 | 0.170 |
Why?
|
| Fusion Regulatory Protein 1, Heavy Chain | 1 | 2021 | 2 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2026 | 430 | 0.170 |
Why?
|
| Folic Acid | 4 | 2016 | 198 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2023 | 393 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 96 | 0.170 |
Why?
|
| Hyperthermia, Induced | 8 | 2000 | 120 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2026 | 7994 | 0.170 |
Why?
|
| Equipment Failure | 6 | 2001 | 115 | 0.170 |
Why?
|
| Students, Pharmacy | 2 | 2016 | 95 | 0.170 |
Why?
|
| Cognition Disorders | 2 | 2016 | 539 | 0.170 |
Why?
|
| Azithromycin | 1 | 2001 | 105 | 0.160 |
Why?
|
| Administration, Oral | 6 | 2024 | 851 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1742 | 0.160 |
Why?
|
| Policy Making | 1 | 2021 | 83 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 1928 | 0.160 |
Why?
|
| Tachycardia, Paroxysmal | 3 | 1995 | 8 | 0.160 |
Why?
|
| Equipment Design | 6 | 2001 | 527 | 0.150 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 360 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 597 | 0.150 |
Why?
|
| Reflex, Abnormal | 1 | 1999 | 8 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 276 | 0.150 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 1180 | 0.150 |
Why?
|
| Immunoglobulin E | 1 | 2021 | 315 | 0.150 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 151 | 0.150 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1999 | 24 | 0.150 |
Why?
|
| Blood Pressure | 6 | 2021 | 1766 | 0.150 |
Why?
|
| Heart Arrest | 3 | 2001 | 406 | 0.150 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 233 | 0.150 |
Why?
|
| Canada | 1 | 2020 | 432 | 0.140 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1999 | 65 | 0.140 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 622 | 0.140 |
Why?
|
| Health Personnel | 1 | 2005 | 746 | 0.140 |
Why?
|
| Cardiologists | 1 | 2018 | 47 | 0.140 |
Why?
|
| Exercise Test | 3 | 2021 | 626 | 0.140 |
Why?
|
| Heart Injuries | 1 | 1999 | 42 | 0.140 |
Why?
|
| Hot Temperature | 1 | 2021 | 410 | 0.140 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 5870 | 0.140 |
Why?
|
| Glucose | 2 | 2023 | 1033 | 0.140 |
Why?
|
| Benzazepines | 1 | 2018 | 35 | 0.140 |
Why?
|
| Monitoring, Ambulatory | 1 | 1999 | 89 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2013 | 519 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1998 | 58 | 0.130 |
Why?
|
| Triazines | 1 | 1998 | 49 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1998 | 37 | 0.130 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 71 | 0.130 |
Why?
|
| Medicare | 3 | 2026 | 899 | 0.130 |
Why?
|
| Health Policy | 3 | 2024 | 398 | 0.130 |
Why?
|
| Diuretics | 1 | 2017 | 68 | 0.130 |
Why?
|
| Dexamethasone | 1 | 1999 | 366 | 0.130 |
Why?
|
| Food, Fortified | 1 | 1997 | 44 | 0.120 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1997 | 56 | 0.120 |
Why?
|
| Patient Participation | 1 | 2020 | 428 | 0.120 |
Why?
|
| Palliative Care | 1 | 2025 | 1011 | 0.120 |
Why?
|
| Mexiletine | 1 | 2016 | 6 | 0.120 |
Why?
|
| Thiocyanates | 1 | 2016 | 27 | 0.120 |
Why?
|
| Thiosulfates | 1 | 2016 | 19 | 0.120 |
Why?
|
| Mitoxantrone | 1 | 1996 | 15 | 0.120 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2006 | 42 | 0.120 |
Why?
|
| Tetralogy of Fallot | 1 | 1997 | 76 | 0.120 |
Why?
|
| Amphetamine | 1 | 2016 | 38 | 0.120 |
Why?
|
| Medication Reconciliation | 2 | 2013 | 31 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 662 | 0.120 |
Why?
|
| Ventricular Function | 1 | 1996 | 54 | 0.120 |
Why?
|
| Neural Tube Defects | 1 | 1997 | 65 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 248 | 0.120 |
Why?
|
| Regression Analysis | 6 | 2016 | 998 | 0.120 |
Why?
|
| Professional Role | 3 | 2025 | 159 | 0.120 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 68 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 6041 | 0.120 |
Why?
|
| Rosuvastatin Calcium | 2 | 2013 | 21 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 67 | 0.120 |
Why?
|
| Hemodynamics | 5 | 2021 | 1113 | 0.120 |
Why?
|
| Amiodarone | 3 | 2001 | 31 | 0.110 |
Why?
|
| Nitroglycerin | 1 | 2015 | 14 | 0.110 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2016 | 93 | 0.110 |
Why?
|
| Societies, Pharmaceutical | 2 | 2013 | 14 | 0.110 |
Why?
|
| Omeprazole | 2 | 2007 | 8 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 1998 | 242 | 0.110 |
Why?
|
| Clinical Competence | 4 | 2012 | 1237 | 0.110 |
Why?
|
| Sex Factors | 3 | 2015 | 2104 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 250 | 0.110 |
Why?
|
| Pre-Excitation Syndromes | 1 | 1995 | 5 | 0.110 |
Why?
|
| Patient Readmission | 3 | 2021 | 765 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 736 | 0.110 |
Why?
|
| Patient Safety | 2 | 2016 | 353 | 0.110 |
Why?
|
| Certification | 2 | 2006 | 118 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 402 | 0.110 |
Why?
|
| Insurance, Disability | 1 | 2014 | 1 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2016 | 182 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 638 | 0.110 |
Why?
|
| Partial Thromboplastin Time | 1 | 2014 | 52 | 0.110 |
Why?
|
| Health Services | 1 | 2015 | 114 | 0.110 |
Why?
|
| Hypoglycemic Agents | 2 | 2005 | 1388 | 0.110 |
Why?
|
| Antidotes | 1 | 2016 | 145 | 0.110 |
Why?
|
| Fever | 1 | 1996 | 313 | 0.110 |
Why?
|
| Risk | 2 | 2017 | 911 | 0.110 |
Why?
|
| Lymphoma | 1 | 1996 | 233 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2005 | 355 | 0.110 |
Why?
|
| Absenteeism | 1 | 2014 | 52 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 167 | 0.100 |
Why?
|
| Prevalence | 3 | 2023 | 2839 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 83 | 0.100 |
Why?
|
| Life Style | 2 | 2018 | 481 | 0.100 |
Why?
|
| Efficiency | 1 | 2014 | 104 | 0.100 |
Why?
|
| Proton Pump Inhibitors | 2 | 2007 | 109 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2000 | 128 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 272 | 0.100 |
Why?
|
| Intensive Care Units | 3 | 2019 | 915 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 221 | 0.100 |
Why?
|
| Mass Casualty Incidents | 1 | 2014 | 49 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2024 | 890 | 0.100 |
Why?
|
| Patient Care Team | 2 | 2025 | 690 | 0.100 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 23 | 0.100 |
Why?
|
| Disease Management | 3 | 2024 | 650 | 0.100 |
Why?
|
| Homicide | 1 | 2014 | 68 | 0.100 |
Why?
|
| Quality Improvement | 3 | 2020 | 1287 | 0.100 |
Why?
|
| Linear Models | 1 | 2016 | 845 | 0.100 |
Why?
|
| Hemorrhage | 4 | 2021 | 813 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2014 | 143 | 0.100 |
Why?
|
| Procainamide | 1 | 1993 | 6 | 0.100 |
Why?
|
| Graft Survival | 2 | 2025 | 510 | 0.090 |
Why?
|
| Calcineurin Inhibitors | 2 | 2010 | 69 | 0.090 |
Why?
|
| Simvastatin | 1 | 2013 | 59 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2018 | 1494 | 0.090 |
Why?
|
| Medical Staff | 1 | 2012 | 17 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2014 | 268 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1537 | 0.090 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 69 | 0.090 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 14 | 0.090 |
Why?
|
| Pancreatitis | 2 | 2005 | 145 | 0.090 |
Why?
|
| Models, Educational | 1 | 2012 | 89 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 115 | 0.090 |
Why?
|
| Dog Diseases | 4 | 1999 | 70 | 0.090 |
Why?
|
| Phenylephrine | 3 | 1999 | 74 | 0.090 |
Why?
|
| Pregnancy | 5 | 2012 | 7122 | 0.090 |
Why?
|
| Maternal Age | 1 | 2012 | 126 | 0.090 |
Why?
|
| Bisoprolol | 1 | 2011 | 2 | 0.090 |
Why?
|
| Acute Disease | 3 | 2018 | 1029 | 0.090 |
Why?
|
| Foundations | 1 | 2011 | 27 | 0.090 |
Why?
|
| Physicians | 1 | 2020 | 949 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3603 | 0.080 |
Why?
|
| Health Services Misuse | 2 | 2020 | 35 | 0.080 |
Why?
|
| Sinoatrial Node | 1 | 1991 | 27 | 0.080 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 111 | 0.080 |
Why?
|
| Research Report | 1 | 2011 | 86 | 0.080 |
Why?
|
| Chronic Pain | 1 | 2015 | 290 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 1 | 2011 | 40 | 0.080 |
Why?
|
| Dogs | 10 | 2000 | 438 | 0.080 |
Why?
|
| Residence Characteristics | 2 | 2012 | 374 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 524 | 0.080 |
Why?
|
| Drug Information Services | 2 | 2013 | 10 | 0.080 |
Why?
|
| Contraindications | 2 | 2002 | 90 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2016 | 5957 | 0.080 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 258 | 0.080 |
Why?
|
| Critical Care | 2 | 2016 | 695 | 0.080 |
Why?
|
| Piperidines | 1 | 1992 | 219 | 0.080 |
Why?
|
| Primary Prevention | 2 | 2010 | 217 | 0.080 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 547 | 0.080 |
Why?
|
| Heart Atria | 3 | 2000 | 141 | 0.080 |
Why?
|
| DNA | 1 | 2016 | 1447 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 341 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2009 | 54 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2012 | 386 | 0.070 |
Why?
|
| Complementary Therapies | 1 | 2010 | 95 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2137 | 0.070 |
Why?
|
| Pregabalin | 1 | 2008 | 12 | 0.070 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2008 | 20 | 0.070 |
Why?
|
| Monoamine Oxidase | 1 | 2008 | 27 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2008 | 41 | 0.070 |
Why?
|
| Pharmacogenetics | 2 | 2020 | 172 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 420 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 695 | 0.070 |
Why?
|
| Cardiomyopathies | 3 | 2017 | 334 | 0.070 |
Why?
|
| Benchmarking | 2 | 2023 | 189 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2008 | 24 | 0.070 |
Why?
|
| Cardiotonic Agents | 2 | 1999 | 94 | 0.070 |
Why?
|
| Ofloxacin | 1 | 2007 | 17 | 0.070 |
Why?
|
| Biological Products | 1 | 2011 | 256 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 820 | 0.070 |
Why?
|
| Levofloxacin | 1 | 2007 | 20 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2009 | 330 | 0.070 |
Why?
|
| Age Factors | 3 | 2009 | 3329 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 252 | 0.070 |
Why?
|
| Peer Review, Research | 1 | 2008 | 36 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 2033 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2001 | 198 | 0.060 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 88 | 0.060 |
Why?
|
| Atrial Function | 2 | 1999 | 10 | 0.060 |
Why?
|
| Combined Modality Therapy | 6 | 2000 | 1268 | 0.060 |
Why?
|
| Amoxicillin | 1 | 2007 | 35 | 0.060 |
Why?
|
| Mucor | 1 | 2007 | 6 | 0.060 |
Why?
|
| Vitamin B 12 | 3 | 2016 | 127 | 0.060 |
Why?
|
| Hypertension | 2 | 2014 | 1262 | 0.060 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 7 | 0.060 |
Why?
|
| Hydantoins | 3 | 2001 | 6 | 0.060 |
Why?
|
| Community Pharmacy Services | 1 | 2007 | 46 | 0.060 |
Why?
|
| Accreditation | 1 | 2007 | 101 | 0.060 |
Why?
|
| Atrial Flutter | 3 | 2000 | 47 | 0.060 |
Why?
|
| Angioedema | 1 | 2006 | 15 | 0.060 |
Why?
|
| Neuralgia | 1 | 2008 | 148 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 2 | 2005 | 115 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 2005 | 248 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 170 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2006 | 167 | 0.060 |
Why?
|
| Professional Autonomy | 1 | 2006 | 29 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2010 | 1056 | 0.060 |
Why?
|
| Creatinine | 2 | 2005 | 509 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2006 | 41 | 0.060 |
Why?
|
| Preceptorship | 1 | 2006 | 63 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2006 | 176 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 117 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2006 | 512 | 0.060 |
Why?
|
| Registries | 1 | 2014 | 2392 | 0.060 |
Why?
|
| alpha-Tocopherol | 2 | 2016 | 32 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3414 | 0.060 |
Why?
|
| Norepinephrine | 3 | 2021 | 196 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 589 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 768 | 0.050 |
Why?
|
| Biotransformation | 1 | 2005 | 63 | 0.050 |
Why?
|
| Critical Illness | 2 | 2025 | 888 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 827 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2005 | 95 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2025 | 50 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 919 | 0.050 |
Why?
|
| Curriculum | 2 | 2016 | 1063 | 0.050 |
Why?
|
| Disease Progression | 2 | 2026 | 2847 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 161 | 0.050 |
Why?
|
| Incidence | 3 | 2023 | 2892 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2006 | 1076 | 0.050 |
Why?
|
| Sarcoma | 3 | 2000 | 203 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2026 | 605 | 0.050 |
Why?
|
| Biological Transport | 1 | 2005 | 418 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 407 | 0.050 |
Why?
|
| Educational Status | 1 | 2006 | 463 | 0.050 |
Why?
|
| Reflex | 2 | 1996 | 70 | 0.050 |
Why?
|
| Ovary | 1 | 2005 | 226 | 0.050 |
Why?
|
| Peroneal Nerve | 2 | 2001 | 18 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2006 | 325 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 422 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2000 | 607 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2001 | 285 | 0.050 |
Why?
|
| Cimetidine | 1 | 2002 | 12 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2002 | 4 | 0.050 |
Why?
|
| Decision Making | 2 | 2019 | 973 | 0.050 |
Why?
|
| Health Status | 1 | 2008 | 834 | 0.050 |
Why?
|
| Facial Neoplasms | 1 | 2002 | 19 | 0.050 |
Why?
|
| Histamine H2 Antagonists | 1 | 2002 | 23 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2006 | 905 | 0.040 |
Why?
|
| HIV Infections | 1 | 2017 | 3148 | 0.040 |
Why?
|
| Recurrence | 3 | 2001 | 1136 | 0.040 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2002 | 78 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2008 | 600 | 0.040 |
Why?
|
| Colorimetry | 1 | 2021 | 12 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 732 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2002 | 80 | 0.040 |
Why?
|
| Patient Selection | 1 | 2006 | 727 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 34 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 743 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 106 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2021 | 73 | 0.040 |
Why?
|
| Mass Screening | 1 | 2010 | 1348 | 0.040 |
Why?
|
| Electrophysiology | 3 | 2000 | 218 | 0.040 |
Why?
|
| Valsalva Maneuver | 1 | 2021 | 10 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 322 | 0.040 |
Why?
|
| Axilla | 1 | 2001 | 51 | 0.040 |
Why?
|
| Sodium Channel Blockers | 1 | 2001 | 23 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2000 | 305 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2001 | 1370 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 23 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 2001 | 47 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 48 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 2000 | 28 | 0.040 |
Why?
|
| Depression | 2 | 2008 | 1561 | 0.040 |
Why?
|
| Action Potentials | 3 | 2000 | 502 | 0.040 |
Why?
|
| Animals | 13 | 2021 | 37948 | 0.040 |
Why?
|
| Retreatment | 1 | 2000 | 77 | 0.040 |
Why?
|
| Volunteers | 1 | 2000 | 39 | 0.040 |
Why?
|
| Bundle of His | 1 | 2000 | 19 | 0.040 |
Why?
|
| Parasympathectomy | 1 | 2000 | 1 | 0.040 |
Why?
|
| Shoulder | 1 | 2001 | 105 | 0.040 |
Why?
|
| Bundle-Branch Block | 1 | 2000 | 36 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2001 | 205 | 0.040 |
Why?
|
| Sarcoma, Experimental | 1 | 2000 | 6 | 0.040 |
Why?
|
| Epidemics | 1 | 2021 | 98 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 6399 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1207 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 182 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 234 | 0.040 |
Why?
|
| Survival Rate | 2 | 2004 | 2089 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 187 | 0.040 |
Why?
|
| Tilt-Table Test | 1 | 1999 | 8 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2021 | 126 | 0.040 |
Why?
|
| Maximum Allowable Concentration | 1 | 1999 | 16 | 0.040 |
Why?
|
| Angelica sinensis | 1 | 1999 | 2 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 1999 | 33 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2006 | 852 | 0.040 |
Why?
|
| Thoracotomy | 2 | 1997 | 80 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 973 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 1999 | 52 | 0.040 |
Why?
|
| Transitional Care | 1 | 2019 | 45 | 0.040 |
Why?
|
| Self Report | 1 | 2024 | 869 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2026 | 2325 | 0.040 |
Why?
|
| Data Display | 1 | 1999 | 20 | 0.040 |
Why?
|
| Weight Loss | 1 | 2005 | 839 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2019 | 64 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 1437 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 1999 | 37 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 1999 | 69 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2019 | 24 | 0.040 |
Why?
|
| Telephone | 3 | 1995 | 176 | 0.040 |
Why?
|
| Cisplatin | 2 | 1993 | 339 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1999 | 32 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2000 | 255 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 1501 | 0.040 |
Why?
|
| Heart Diseases | 2 | 2005 | 341 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 709 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1999 | 352 | 0.030 |
Why?
|
| Heart Ventricles | 2 | 2000 | 751 | 0.030 |
Why?
|
| Delirium | 1 | 2019 | 105 | 0.030 |
Why?
|
| Heart Failure, Systolic | 1 | 2018 | 27 | 0.030 |
Why?
|
| Echocardiography | 2 | 1998 | 644 | 0.030 |
Why?
|
| Hydrogen | 1 | 1998 | 75 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2019 | 120 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2006 | 1668 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 169 | 0.030 |
Why?
|
| Heart Block | 1 | 1997 | 40 | 0.030 |
Why?
|
| Child | 3 | 2015 | 22600 | 0.030 |
Why?
|
| Resuscitation | 1 | 2000 | 310 | 0.030 |
Why?
|
| Cannabis | 1 | 2024 | 509 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2000 | 248 | 0.030 |
Why?
|
| Digoxin | 1 | 1997 | 27 | 0.030 |
Why?
|
| Bread | 1 | 1997 | 3 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 164 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2010 | 5185 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1997 | 34 | 0.030 |
Why?
|
| Edible Grain | 1 | 1997 | 48 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1998 | 570 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1994 | 625 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 1997 | 77 | 0.030 |
Why?
|
| Energy Intake | 1 | 2019 | 501 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 1995 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 7 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 31 | 0.030 |
Why?
|
| Frailty | 1 | 2019 | 200 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1996 | 55 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 1996 | 85 | 0.030 |
Why?
|
| Anesthetics | 1 | 2017 | 99 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 373 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 277 | 0.030 |
Why?
|
| Surface Properties | 1 | 1997 | 397 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 92 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 427 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 589 | 0.030 |
Why?
|
| Neutropenia | 1 | 1996 | 155 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 391 | 0.030 |
Why?
|
| Factor X | 1 | 2014 | 25 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 1076 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 231 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 454 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 379 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 1996 | 202 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 185 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 1994 | 71 | 0.030 |
Why?
|
| PubMed | 1 | 2013 | 15 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 539 | 0.020 |
Why?
|
| Medical Assistance | 1 | 2013 | 13 | 0.020 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2013 | 12 | 0.020 |
Why?
|
| Acecainide | 1 | 1993 | 2 | 0.020 |
Why?
|
| Reoperation | 1 | 2016 | 624 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 1994 | 331 | 0.020 |
Why?
|
| Heparin | 1 | 2014 | 243 | 0.020 |
Why?
|
| Disaster Planning | 1 | 2014 | 101 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2013 | 80 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1993 | 114 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 72 | 0.020 |
Why?
|
| Antibodies | 1 | 2014 | 396 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 368 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 581 | 0.020 |
Why?
|
| Education | 1 | 2012 | 105 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1995 | 330 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2016 | 941 | 0.020 |
Why?
|
| Biological Availability | 1 | 1992 | 143 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 31 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 154 | 0.020 |
Why?
|
| Stroke | 1 | 2021 | 1262 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 220 | 0.020 |
Why?
|
| Urinary Retention | 1 | 2011 | 24 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Random Allocation | 1 | 1992 | 366 | 0.020 |
Why?
|
| Self Care | 1 | 2014 | 389 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 327 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1995 | 388 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 167 | 0.020 |
Why?
|
| Kidney | 1 | 2019 | 1495 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 1134 | 0.020 |
Why?
|
| Body Temperature | 1 | 1992 | 226 | 0.020 |
Why?
|
| Neutrophils | 1 | 1996 | 1118 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 91 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1889 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 586 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 1327 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 794 | 0.020 |
Why?
|
| Micronutrients | 1 | 2010 | 101 | 0.020 |
Why?
|
| Heart | 2 | 1995 | 626 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2009 | 29 | 0.020 |
Why?
|
| Biomarkers | 2 | 2016 | 4261 | 0.020 |
Why?
|
| Food | 1 | 2010 | 148 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2942 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 707 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 1987 | 42 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 848 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2012 | 692 | 0.020 |
Why?
|
| Internship, Nonmedical | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2006 | 130 | 0.020 |
Why?
|
| Specialty Boards | 1 | 2006 | 42 | 0.020 |
Why?
|
| Schools, Pharmacy | 1 | 2006 | 48 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 309 | 0.010 |
Why?
|
| Caregivers | 1 | 2015 | 1062 | 0.010 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2005 | 3 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2754 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2000 | 562 | 0.010 |
Why?
|
| Furosemide | 1 | 2005 | 37 | 0.010 |
Why?
|
| Faculty | 1 | 2006 | 153 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 52 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 495 | 0.010 |
Why?
|
| Temperature | 3 | 1999 | 680 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 85 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2004 | 21 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 200 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 293 | 0.010 |
Why?
|
| Azathioprine | 1 | 2004 | 44 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1996 | 2201 | 0.010 |
Why?
|
| Gout | 1 | 2005 | 35 | 0.010 |
Why?
|
| Diphosphonates | 1 | 2005 | 68 | 0.010 |
Why?
|
| Everolimus | 1 | 2004 | 112 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1994 | 3888 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 89 | 0.010 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 120 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 120 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 392 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 243 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 18261 | 0.010 |
Why?
|
| Myocardial Contraction | 2 | 1999 | 288 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 751 | 0.010 |
Why?
|
| Infection Control | 1 | 2005 | 174 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1993 | 2326 | 0.010 |
Why?
|
| Sirolimus | 1 | 2004 | 280 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 319 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 1161 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2004 | 314 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 835 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1844 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 267 | 0.010 |
Why?
|
| Cheek | 1 | 2002 | 16 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2005 | 351 | 0.010 |
Why?
|
| Methylmalonic Acid | 1 | 2002 | 66 | 0.010 |
Why?
|
| Mohs Surgery | 1 | 2002 | 29 | 0.010 |
Why?
|
| Legislation, Medical | 1 | 2001 | 11 | 0.010 |
Why?
|
| Device Approval | 1 | 2001 | 19 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 236 | 0.010 |
Why?
|
| Homocysteine | 1 | 2002 | 152 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 480 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2004 | 452 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1705 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2000 | 30 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 2000 | 26 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 1999 | 16 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1999 | 14 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2002 | 236 | 0.010 |
Why?
|
| Epinephrine | 1 | 2000 | 154 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2000 | 351 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1999 | 288 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2000 | 284 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 1079 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1999 | 132 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2004 | 971 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 255 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 419 | 0.010 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 14 | 0.010 |
Why?
|
| Oxygen | 1 | 2000 | 984 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1995 | 110 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 8 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1993 | 47 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1993 | 30 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1993 | 25 | 0.010 |
Why?
|
| Half-Life | 1 | 1993 | 152 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1993 | 48 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1993 | 19 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1993 | 119 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 288 | 0.010 |
Why?
|
| Phosphates | 1 | 1994 | 177 | 0.010 |
Why?
|
| Survivors | 1 | 1996 | 519 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1992 | 52 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 1322 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1993 | 513 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1994 | 501 | 0.010 |
Why?
|
| Hepatitis, Animal | 1 | 1987 | 2 | 0.000 |
Why?
|
| Endocardium | 1 | 1987 | 31 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1987 | 115 | 0.000 |
Why?
|
| Tachycardia | 1 | 1987 | 57 | 0.000 |
Why?
|
| Peritonitis | 1 | 1987 | 83 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1987 | 335 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1987 | 195 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1987 | 1046 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1987 | 501 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1987 | 393 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 11790 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1987 | 4539 | 0.000 |
Why?
|